MR Cerebral Blood Volume Maps Correlated with Vascular Endothelial Growth Factor Expression and Tumor Grade in Nonenhancing Gliomas

References

1. ↵
   Kleihues P, Cayenee W. Pathology and Genetics of Tumors of the Nervous System. Lyon: International Agency for Research on Cancer;2000
2. ↵
   Wenz F, Rempp K, Hess T, et al. Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 1996;166:187–193

   PubMed
3. Tomoi M, Maeda M, Yoshida M, et al. Assessment of radiotherapeutic effect on brain tumors by dynamic susceptibility contrast MR imaging: a preliminary report. Radiat Med 1999;17:195–199

   PubMed
4. Pardo FS, Aronen HJ, Kennedy D, et al. Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. Int J Radiat Oncol Biol Phys 1994;30:663–669

   PubMed
5. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901–909

   Abstract/FREE Full Text
6. Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 2000;21:357–366

   Abstract/FREE Full Text
7. ↵
   Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362–372

   CrossRefPubMedWeb of Science
8. ↵
   Barker FG II, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936–941

   CrossRefPubMedWeb of Science
9. ↵
   Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59:947–949

   Abstract/FREE Full Text
10. ↵
    Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479–1486

    CrossRefPubMedWeb of Science
11. ↵
    Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

    PubMedWeb of Science
12. ↵
    Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–798

    CrossRefPubMedWeb of Science
13. ↵
    Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002;178:711–716

    CrossRefPubMedWeb of Science
14. Cha S, Lu S, Johnson G, Knopp EA. Dynamic susceptibility contrast MR imaging: correlation of signal intensity changes with cerebral blood volume measurements. J Magn Reson Imaging 2000;11:114–119

    CrossRefPubMed
15. Lam WW, Chan KW, Wong WL, Poon WS, Metreweli C. Pre-operative grading of intracranial glioma. Acta Radiol 2001;42:548–554

    PubMed
16. ↵
    Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–1998

    Abstract/FREE Full Text
17. ↵
    Uematsu H, Maeda M, Sadato N, et al. Blood volume of gliomas determined by double-echo dynamic perfusion-weighted MR imaging: a preliminary study. AJNR Am J Neuroradiol 2001;22:1915–1919

    Abstract/FREE Full Text
18. ↵
    Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol 2000;50(1–2):109–120
19. ↵
    Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998;88:513–520

    PubMedWeb of Science
20. ↵
    Pietsch T, Valter MM, Wolf HK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 1997;93:109–117

    CrossRefPubMed
21. ↵
    Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 1998;24:29–35

    CrossRefPubMedWeb of Science
22. ↵
    Pradel C, Siauve N, Bruneteau G, et al. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 2003;21:845–851

    CrossRefPubMed
23. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;89:1889–1895

    CrossRefPubMed
24. Checkley D, Tessier JJ, Wedge SR, et al. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signaling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging 2003;21:475–482

    CrossRefPubMed
25. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484–1493

    Abstract/FREE Full Text
26. Pham CD, Roberts TP, van Bruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225–230

    CrossRefPubMedWeb of Science
27. ↵
    Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro-oncology 2003;5:235–243

    Abstract/FREE Full Text
28. ↵
    Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803

    CrossRefPubMedWeb of Science
29. ↵
    Bouza A. Desenvolvimento de uma técnica para fusão de imagens para planejamento cirúrgico em condições estereotáxicas: Tese de Mestrado em Neurociências. São Paulo, Brazil: UNIFESP-EPM,1999
30. ↵
    Gilles FH, Brown WD, Leviton A, et al. Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors: Children Brain Tumor Consortium. Cancer 2000;88:1477–1483

    CrossRefPubMedWeb of Science
31. ↵
    Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncology 2001;3:193–200

    Abstract/FREE Full Text
32. ↵
    Chaudhry IH, O’Donovan DG, Brenchley PE, Reid H, Roberts IS. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001;39:409–415

    CrossRefPubMedWeb of Science
33. ↵
    Frapazz D, Chinot O, Bataillard A, et al. Summary version of standards, options and recomendations for the management of adult patients with intracranial glioma. Br J Cancer 2003;89:S73–S83

    CrossRefPubMedWeb of Science
34. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 1992;31:431–436

    CrossRefPubMedWeb of Science
35. Vecht CJ. Effect of age on treatment decisions in low-grade glioma. J Neurol Neurosurg Psychiatry 1993;56:1259–1264

    Abstract/FREE Full Text
36. ↵
    DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114–123

    CrossRefPubMedWeb of Science
37. ↵
    Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323–331

    CrossRefPubMedWeb of Science
38. ↵
    Cairncross JG, Laperriere NJ. Low-grade glioma. To treat or not to treat? Arch Neurol 1989;46:1238–1239

    CrossRefPubMedWeb of Science
39. ↵
    Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001;95:735–745

    PubMedWeb of Science
40. ↵
    Sawaya R. Extent of resection in malignant gliomas: a critical summary. J Neurooncol 1999;42:303–305

    CrossRefPubMed
41. ↵
    Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001;2:667–673

    CrossRefPubMedWeb of Science
42. ↵
    Klagsbrun M, D’Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7:259–270

    CrossRefPubMed
43. ↵
    Risau W. What, if anything, is an angiogenic factor? Cancer Metastasis Rev 1996;15:149–151

    CrossRefPubMedWeb of Science
44. ↵
    Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–364

    CrossRefPubMedWeb of Science
45. ↵
    Klagsbrun M, D’Amore PA. Regulators of angiogenesis. Ann Rev Physiol 1991;53:217–239

    CrossRefPubMedWeb of Science
46. ↵
    Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000;50:121–137

    CrossRefPubMed
47. ↵
    Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 1999;44(4):732–740
48. Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993;91:153–159

    CrossRefPubMedWeb of Science
49. ↵
    Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995;55:1189–1193

    Abstract/FREE Full Text
50. ↵
    Bird CR, Drayer BP, Medina M, Rekate HL, Flom RA, Hodak JA. Gd-DTPA-enhanced MR imaging in pediatric patients after brain tumor resection. Radiology 1988;169:123–126

    PubMedWeb of Science
51. ↵
    Lee SJ, Kim JH, Kim YM, et al. Perfusion MR imaging in gliomas: comparison with histologic tumor grade. Korean J Radiol 2001;2:1–7

    PubMed
52. ↵
    Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas. AJNR Am J Neuroradiol 2004;25:214–221

    Abstract/FREE Full Text
53. ↵
    Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555–566

    CrossRefPubMedWeb of Science
54. ↵
    Abu-Hajir M, Rand SD, Krouwer HG, Schmainda KM. Noninvasive assessment of neoplastic angiogenesis: the role of magnetic resonance imaging. Semin Thromb Hemost 2003;29:309–315

    CrossRefPubMed
55. ↵
    Donahue KM, Krouwer HG, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000;43:845–853

    CrossRefPubMedWeb of Science
56. ↵
    Chan AS, Leung SY, Wong MP, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998;22:816–826

    CrossRefPubMedWeb of Science
57. ↵
    Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M. Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl) 1998;96:453–462

    CrossRefPubMed